Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2026)

Royalty Pharma has reported Other Non-Current Liabilities for 7 years, with the latest figure at $648.7 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 3523.87% year-over-year to $648.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $648.7 million (up 3523.87% YoY) and the FY2025 annual result came in at $120.8 million, changed N/A from the prior year.
• Other Non-Current Liabilities grew to $648.7 million in Q1 2026 per RPRX's latest filing, from $120.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $648.7 million in Q1 2026 and troughed at $900000.0 in Q4 2023.
• A 5-year average of $103.9 million and a median of $12.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities slumped 80.55% in 2023, then soared 8913.23% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $2.5 million in 2022, then sank by 64.0% to $900000.0 in 2023, then jumped by 520.0% to $5.6 million in 2024, then jumped by 2065.65% to $120.8 million in 2025, then soared by 436.79% to $648.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $648.7 million, $120.8 million, and $502.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.